NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

Home・Aktien・Roche Holding AG

Roche Holding AG

Open

BrancheGesundheitswesen

338 -0.35

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

337.8

Max

341.4

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.8B 5.5B
Verkäufe	15B 31B
KGV Branchendurchschnitt	21.01 49.701
Dividendenrendite	2.98
Gewinnspanne	17.892
Angestellte	103,249
EBITDA	5.1B 12B

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	2.98% 2.39%

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-21B 268B
Vorheriger Eröffnungskurs	338.35
Vorheriger Schlusskurs	338

Nachrichtenstimmung

By Acuity

27%

73%

65 / 345 Ranking in Healthcare

Roche Holding AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Mai 2026, 06:06 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools

23. Apr. 2026, 07:46 UTC

Ergebnisse

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23. Apr. 2026, 05:40 UTC

Ergebnisse

Roche Backs Full-Year View as Quarterly Sales Rise

9. März 2026, 16:43 UTC

Wichtige Markttreiber

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9. März 2026, 15:44 UTC

Wichtige Markttreiber

Correction to Roche Shares Article

9. März 2026, 09:51 UTC

Wichtige Markttreiber

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6. März 2026, 09:24 UTC

Wichtige Markttreiber

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

13. Mai 2026, 10:20 UTC

Market Talk

Ergebnisse

Roche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk

7. Mai 2026, 05:53 UTC

Akquisitionen, Fusionen, Übernahmen

Correct: Roche to Buy PathAI for up to $1.05B

7. Mai 2026, 05:07 UTC

Akquisitionen, Fusionen, Übernahmen

Roche: Acquisition Expected to Complete in 2H

7. Mai 2026, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Roche: Closing of Deal Subject to Customary Closing Conditions

7. Mai 2026, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Pay $750M Upfront, Milestone Payments of Up to $300M

7. Mai 2026, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy PathAI for up to $1.5B

7. Mai 2026, 05:05 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy PathAI

6. Mai 2026, 22:50 UTC

Ergebnisse

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

27. Apr. 2026, 09:54 UTC

Market Talk

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

23. Apr. 2026, 08:10 UTC

Market Talk

Ergebnisse

Roche Reports In Line Sales Figures -- Market Talk

23. Apr. 2026, 05:04 UTC

Ergebnisse

Roche Backs 2026 View

23. Apr. 2026, 05:04 UTC

Ergebnisse

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23. Apr. 2026, 05:03 UTC

Ergebnisse

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23. Apr. 2026, 05:02 UTC

Ergebnisse

Roche 1Q Group Sales Up 6% at Constant Currency

23. Apr. 2026, 05:02 UTC

Ergebnisse

Analysts Saw Roche 1Q Sales at CHF14.73B

23. Apr. 2026, 05:01 UTC

Ergebnisse

Roche 1Q Sales CHF14.72B

10. Apr. 2026, 11:28 UTC

Market Talk

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10. Apr. 2026, 11:17 UTC

Market Talk

Roche to Face Significant Currency Headwinds -- Market Talk

11. März 2026, 10:57 UTC

Market Talk

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9. März 2026, 09:43 UTC

Heiße Aktien

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6. März 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3. März 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2. März 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

Peer-Vergleich

Kursveränderung

Roche Holding AG Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Roche Holding AG – Dist abgegeben haben.

Stimmung

By Acuity

65 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Andere Aktien aus dem Sektor

NOVN.CH

Novartis AG

119.52

↑ +0.02%

Roche Holding AG

Übersicht

Veränderung der Aktienkurses

Schlüsselkennzahlen

Dividenden

Marktstatistiken

Nachrichtenstimmung

Roche Holding AG Chart

Ähnliche Nachrichten

Peer-Vergleich

Roche Holding AG Prognose

Rating-Konsens

Stimmung

Finanzen

Über Roche Holding AG

Andere Aktien aus dem Sektor